---
document_datetime: 2025-12-17 23:15:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tobi-podhaler.html
document_name: tobi-podhaler.html
version: success
processing_time: 0.145824
conversion_datetime: 2025-12-28 10:10:13.604544
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tobi Podhaler

[RSS](/en/individual-human-medicine.xml/65935)

##### Authorised

This medicine is authorised for use in the European Union

tobramycin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76463)
- [More information on Tobi Podhaler](#more-information-on-tobi-podhaler-566)
- [More information on Tobi Podhaler](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Tobi Podhaler. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tobi Podhaler.

Expand section

Collapse section

## What is Tobi Podhaler?

Tobi Podhaler is a medicine that contains the active substance tobramycin. It is available as capsules (28 mg) containing a dry powder for inhalation using a portable inhaler device.

## What is Tobi Podhaler used for?

Tobi Podhaler is used to suppress chronic lung infection caused by bacteria called *Pseudomonas aeruginosa* in adults and children aged 6 years and over who have cystic fibrosis. Cystic fibrosis is an inherited disease in which there is accumulation of thick mucus in the lungs that allows bacteria to grow more easily causing infections. *P. aeruginosa* is a frequent cause of infections in cystic fibrosis patients.

Because the number of patients with cystic fibrosis and *P. aeruginosa* bacterial lung infection is low, the disease is considered 'rare' and Tobi Podhaler was designated an 'orphan medicine' (a medicine used in rare diseases) on 17 March 2003.

The medicine can only be obtained with a prescription.

## How is Tobi Podhaler used?

Tobi Podhaler is inhaled using a hand-held device called Podhaler. The capsules are only to be inserted into the Podhaler and must never be swallowed. The recommended dose is four capsules twice a day (as close as possible to 12 hour intervals) for four weeks, followed by four weeks without treatment. The patient should continue with a cycle of four weeks 'on' treatment followed by four weeks 'off' treatment for as long as the doctor believes the patient is benefiting from it. If the patient's lung infection gets worse, the doctor should consider replacing or adding another treatment to Tobi Podhaler. For more information on how to use Tobi Podhaler, see the instructions in the package leaflet.

## How does Tobi Podhaler work?

The active substance in Tobi Podhaler, tobramycin, is an antibiotic that belongs to the group 'aminoglycosides'. It works by disrupting the production of proteins that *P. aeruginosa* needs to build its cell walls. This damages the bacteria and eventually kills them.

Tobramycin is a well-known antibiotic that has been used to treat lung infection in cystic fibrosis patients, available in the form of a solution used with a nebuliser (a machine that changes a solution into an aerosol that the patient can breathe in). Tobi Podhaler is intended to increase the convenience of taking tobramycin for patients.

## How has Tobi Podhaler been studied?

The applicant presented data on an existing nebuliser solution containing tobramycin called Tobi. They also presented data from the published literature.

Tobi Podhaler was studied in two main trials in patients who had cystic fibrosis with *P. aeruginosa* lung infection. The first trial, which involved 102 patients aged 6 to 21 years, compared Tobi Podhaler with placebo (a dummy treatment), while the second, involving 553 mostly adult patients, compared it with Tobi. The trials lasted 24 weeks (three treatment cycles). The main measure of effectiveness was the change in FEV 1 at the end of the treatment period of cycle 1 in the first study and at the end of the treatment period of cycle 3 in the second study. FEV 1 is the most air a person can breathe out in one second.

## What benefit has Tobi Podhaler shown during the studies?

Tobi Podhaler was more effective than placebo in treating *P. aeruginosa* infection in patients with cystic fibrosis. After four weeks of treatment, the patients taking Tobi Podhaler had an improvement in FEV1 of 13.2%, while patients taking placebo had a reduction in FEV1 of around 0.6%. When the patients in the placebo group were switched to Tobi Podhaler for the second and third cycles they also experienced a similar improvement in FEV1. The effect of Tobi Podhaler was similar to that of Tobi after three cycles of treatment.

## What is the risk associated with Tobi Podhaler?

The most common side effects with Tobi Podhaler (seen in more than 1 patient in 10) are haemoptysis (coughing up blood), dyspnoea (difficulty breathing), dysphonia (hoarseness), cough and productive cough (producing mucus), oropharyngeal pain (affecting the mouth and throat) and pyrexia (fever). For the full list of all side effects reported with Tobi Podhaler, see the package leaflet.

Tobi Podhaler must not be used in people who are hypersensitive (allergic) to tobramycin, any aminoglycoside or any of the other ingredients.

## Why has Tobi Podhaler been approved?

The CHMP decided that Tobi Podhaler's benefits are greater than its risks, since it is effective at treating lung infection in cystic fibrosis patients and given its added convenience for patients. The Committee therefore recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Tobi Podhaler?

A risk management plan has been developed to ensure that Tobi Podhaler is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tobi Podhaler, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Tobi Podhaler

The European Commission granted a marketing authorisation valid throughout the European Union for Tobi Podhaler on 20 July 2011.

For more information about treatment with Tobi Podhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Tobi Podhaler : EPAR - Summary for the public

Reference Number: EMA/614187/2010

English (EN) (79.81 KB - PDF)

**First published:** 25/08/2011

**Last updated:** 22/03/2016

[View](/en/documents/overview/tobi-podhaler-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-841)

български (BG) (112.58 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/bg/documents/overview/tobi-podhaler-epar-summary-public_bg.pdf)

español (ES) (78.68 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/es/documents/overview/tobi-podhaler-epar-summary-public_es.pdf)

čeština (CS) (104.14 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/cs/documents/overview/tobi-podhaler-epar-summary-public_cs.pdf)

dansk (DA) (77.62 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/da/documents/overview/tobi-podhaler-epar-summary-public_da.pdf)

Deutsch (DE) (79.54 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/de/documents/overview/tobi-podhaler-epar-summary-public_de.pdf)

eesti keel (ET) (77.31 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/et/documents/overview/tobi-podhaler-epar-summary-public_et.pdf)

ελληνικά (EL) (108.86 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/el/documents/overview/tobi-podhaler-epar-summary-public_el.pdf)

français (FR) (78.86 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/fr/documents/overview/tobi-podhaler-epar-summary-public_fr.pdf)

hrvatski (HR) (98.96 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/hr/documents/overview/tobi-podhaler-epar-summary-public_hr.pdf)

italiano (IT) (77.72 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/it/documents/overview/tobi-podhaler-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.86 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/lv/documents/overview/tobi-podhaler-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (101.64 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/lt/documents/overview/tobi-podhaler-epar-summary-public_lt.pdf)

magyar (HU) (98.53 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/hu/documents/overview/tobi-podhaler-epar-summary-public_hu.pdf)

Malti (MT) (105.06 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/mt/documents/overview/tobi-podhaler-epar-summary-public_mt.pdf)

Nederlands (NL) (78.16 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/nl/documents/overview/tobi-podhaler-epar-summary-public_nl.pdf)

polski (PL) (105.57 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/pl/documents/overview/tobi-podhaler-epar-summary-public_pl.pdf)

português (PT) (78.52 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/pt/documents/overview/tobi-podhaler-epar-summary-public_pt.pdf)

română (RO) (99.87 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/ro/documents/overview/tobi-podhaler-epar-summary-public_ro.pdf)

slovenčina (SK) (104 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/sk/documents/overview/tobi-podhaler-epar-summary-public_sk.pdf)

slovenščina (SL) (97.96 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/sl/documents/overview/tobi-podhaler-epar-summary-public_sl.pdf)

Suomi (FI) (77.35 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/fi/documents/overview/tobi-podhaler-epar-summary-public_fi.pdf)

svenska (SV) (78.08 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

22/03/2016

[View](/sv/documents/overview/tobi-podhaler-epar-summary-public_sv.pdf)

## Product information

Tobi Podhaler : EPAR - Product Information

English (EN) (866.45 KB - PDF)

**First published:** 25/08/2011

**Last updated:** 11/12/2025

[View](/en/documents/product-information/tobi-podhaler-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-634)

български (BG) (851.89 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/bg/documents/product-information/tobi-podhaler-epar-product-information_bg.pdf)

español (ES) (610.4 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/es/documents/product-information/tobi-podhaler-epar-product-information_es.pdf)

čeština (CS) (614.88 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/cs/documents/product-information/tobi-podhaler-epar-product-information_cs.pdf)

dansk (DA) (561.95 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/da/documents/product-information/tobi-podhaler-epar-product-information_da.pdf)

Deutsch (DE) (650.99 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/de/documents/product-information/tobi-podhaler-epar-product-information_de.pdf)

eesti keel (ET) (666.47 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/et/documents/product-information/tobi-podhaler-epar-product-information_et.pdf)

ελληνικά (EL) (701.04 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/el/documents/product-information/tobi-podhaler-epar-product-information_el.pdf)

français (FR) (556.29 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/fr/documents/product-information/tobi-podhaler-epar-product-information_fr.pdf)

hrvatski (HR) (796.12 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/hr/documents/product-information/tobi-podhaler-epar-product-information_hr.pdf)

íslenska (IS) (563.7 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/is/documents/product-information/tobi-podhaler-epar-product-information_is.pdf)

italiano (IT) (634.19 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/it/documents/product-information/tobi-podhaler-epar-product-information_it.pdf)

latviešu valoda (LV) (352.09 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/lv/documents/product-information/tobi-podhaler-epar-product-information_lv.pdf)

lietuvių kalba (LT) (690.58 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/lt/documents/product-information/tobi-podhaler-epar-product-information_lt.pdf)

magyar (HU) (640.55 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/hu/documents/product-information/tobi-podhaler-epar-product-information_hu.pdf)

Malti (MT) (714.26 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/mt/documents/product-information/tobi-podhaler-epar-product-information_mt.pdf)

Nederlands (NL) (754.66 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/nl/documents/product-information/tobi-podhaler-epar-product-information_nl.pdf)

norsk (NO) (622.47 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/no/documents/product-information/tobi-podhaler-epar-product-information_no.pdf)

polski (PL) (669.48 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/pl/documents/product-information/tobi-podhaler-epar-product-information_pl.pdf)

português (PT) (591.55 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/pt/documents/product-information/tobi-podhaler-epar-product-information_pt.pdf)

română (RO) (662.4 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/ro/documents/product-information/tobi-podhaler-epar-product-information_ro.pdf)

slovenčina (SK) (786.17 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/sk/documents/product-information/tobi-podhaler-epar-product-information_sk.pdf)

slovenščina (SL) (597.26 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/sl/documents/product-information/tobi-podhaler-epar-product-information_sl.pdf)

Suomi (FI) (415.53 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/fi/documents/product-information/tobi-podhaler-epar-product-information_fi.pdf)

svenska (SV) (391.79 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

11/12/2025

[View](/sv/documents/product-information/tobi-podhaler-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000316739 11/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tobi Podhaler : EPAR - All Authorised presentations

English (EN) (22.61 KB - PDF)

**First published:** 25/08/2011

**Last updated:** 25/08/2011

[View](/en/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-348)

български (BG) (95.28 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/bg/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.16 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/es/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_es.pdf)

čeština (CS) (88.84 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/cs/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22.91 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/da/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (22.82 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/de/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (23.23 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/et/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (88.69 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/el/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_el.pdf)

français (FR) (23.08 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/fr/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (211.32 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/hr/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (23.07 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/is/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_is.pdf)

italiano (IT) (22.59 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/it/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (89.58 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/lv/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (89.14 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/lt/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (144.88 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/hu/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (90.78 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/mt/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.47 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/nl/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.09 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/no/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_no.pdf)

polski (PL) (91.23 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/pl/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.13 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/pt/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_pt.pdf)

română (RO) (87.84 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/ro/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (89.93 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/sk/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (58.64 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/sl/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.89 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/fi/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.03 KB - PDF)

**First published:**

25/08/2011

**Last updated:**

25/08/2011

[View](/sv/documents/all-authorised-presentations/tobi-podhaler-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tobi Podhaler Active substance tobramycin International non-proprietary name (INN) or common name tobramycin Therapeutic area (MeSH)

- Cystic Fibrosis
- Respiratory Tract Infections

Anatomical therapeutic chemical (ATC) code J01GB01

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Tobi Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to *Pseudomonas aeruginosa* in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/002155 Marketing authorisation holder

Viatris Healthcare Limited

Damastown Industrial Park Mulhuddart Dublin 15 Dublin Ireland

Opinion adopted 23/09/2010 Marketing authorisation issued 20/07/2011 Revision 24

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tobi Podhaler : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.53 KB - PDF)

**First published:** 11/12/2025

[View](/en/documents/procedural-steps-after/tobi-podhaler-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tobi Podhaler : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (262.51 KB - PDF)

**First published:** 03/05/2012

**Last updated:** 11/12/2025

[View](/en/documents/procedural-steps-after/tobi-podhaler-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

TOBI Podhaler : H/C/PSUSA/00009315/202406 - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/164174/2025

English (EN) (93.71 KB - PDF)

**First published:** 13/05/2025

[View](/en/documents/scientific-conclusion/tobi-podhaler-h-c-psusa-00009315-202406-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

TOBI Podhaler-H-C-002155-P46-030: EPAR - Assessment report

Adopted

Reference Number: EMA/220887/2023

English (EN) (481.39 KB - PDF)

**First published:** 05/06/2023

[View](/en/documents/variation-report/tobi-podhaler-h-c-002155-p46-030-epar-assessment-report_en.pdf)

TOBI Podhaler-H-C-002155-P46-031: EPAR - Assessment report

Adopted

Reference Number: EMA/220907/2023

English (EN) (348.95 KB - PDF)

**First published:** 05/06/2023

[View](/en/documents/variation-report/tobi-podhaler-h-c-002155-p46-031-epar-assessment-report_en.pdf)

TOBI Podhaler-H-C-002155-P46-033: EPAR - Assessment report

Adopted

Reference Number: EMA/220904/2023

English (EN) (436.89 KB - PDF)

**First published:** 05/06/2023

[View](/en/documents/variation-report/tobi-podhaler-h-c-002155-p46-033-epar-assessment-report_en.pdf)

TOBI Podhaler-H-C-002155-P46-0034 : EPAR - Assessment Report

Adopted

English (EN) (261.53 KB - PDF)

**First published:** 14/04/2023

[View](/en/documents/variation-report/tobi-podhaler-h-c-002155-p46-0034-epar-assessment-report_en.pdf)

Tobi Podhaler-H-C-2155-P46-0027: EPAR - Assessment Report

Adopted

Reference Number: EMA/533035/2016

English (EN) (886.77 KB - PDF)

**First published:** 05/08/2016

**Last updated:** 05/08/2016

[View](/en/documents/variation-report/tobi-podhaler-h-c-2155-p46-0027-epar-assessment-report_en.pdf)

Tobi Podhaler-H-C-2155-P46-0029 : EPAR - Assessment Report

Adopted

Reference Number: EMA/451636/2016

English (EN) (626.73 KB - PDF)

**First published:** 05/07/2016

**Last updated:** 05/07/2016

[View](/en/documents/variation-report/tobi-podhaler-h-c-2155-p46-0029-epar-assessment-report_en.pdf)

Tobi Podhaler-H-C-2155-P46-0028 : EPAR - Assessment Report

Adopted

Reference Number: EMA/194399/2016

English (EN) (3.07 MB - PDF)

**First published:** 15/03/2016

**Last updated:** 15/03/2016

[View](/en/documents/variation-report/tobi-podhaler-h-c-2155-p46-0028-epar-assessment-report_en.pdf)

Tobi Podhaler-H-C-2155-P46-0026: EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/780249/2015

English (EN) (443.84 KB - PDF)

**First published:** 17/12/2015

**Last updated:** 17/12/2015

[View](/en/documents/variation-report/tobi-podhaler-h-c-2155-p46-0026-epar-assessment-report_en.pdf)

Tobi Podhaler-H-C-2155-P46-0024 : EPAR - Assessment Report

Adopted

Reference Number: EMA/589999/2015

English (EN) (631.89 KB - PDF)

**First published:** 15/10/2015

**Last updated:** 15/10/2015

[View](/en/documents/variation-report/tobi-podhaler-h-c-2155-p46-0024-epar-assessment-report_en.pdf)

Tobi Podhaler : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/759531/2014

English (EN) (63.75 KB - PDF)

**First published:** 23/01/2015

**Last updated:** 23/01/2015

[View](/en/documents/pip-compliance/tobi-podhaler-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Tobi Podhaler-H-C-2155-II-0027-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/701057/2014

English (EN) (459.82 KB - PDF)

**First published:** 23/01/2015

**Last updated:** 23/01/2015

[View](/en/documents/variation-report/tobi-podhaler-h-c-2155-ii-0027-g-epar-assessment-report-variation_en.pdf)

Tobi Podhaler-H-C-2155-PSUV-0015 : EPAR - Scientific conclusion and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/443412/2013

English (EN) (78.96 KB - PDF)

**First published:** 16/12/2013

**Last updated:** 16/12/2013

[View](/en/documents/scientific-conclusion/tobi-podhaler-h-c-2155-psuv-0015-epar-scientific-conclusion-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Tobi Podhaler : EPAR - Public assessment report

Adopted

English (EN) (574.47 KB - PDF)

**First published:** 25/08/2011

**Last updated:** 25/08/2011

[View](/en/documents/assessment-report/tobi-podhaler-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tobi Podhaler

Adopted

Reference Number: EMA/CHMP/571131/2010

English (EN) (50.93 KB - PDF)

**First published:** 24/09/2010

**Last updated:** 24/09/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tobi-podhaler_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Tobi Podhaler : EPAR - Product information - tracked changes

English (EN) (625.5 KB - DOC)

**First published:** 14/05/2025

[View](/en/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_en.doc)

[Other languages (24)](#file-language-dropdown-35)

български (BG) (488.22 KB - DOCX)

**First published:**

14/05/2025

[View](/bg/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_bg.docx)

español (ES) (472.68 KB - DOCX)

**First published:**

14/05/2025

[View](/es/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_es.docx)

čeština (CS) (468.22 KB - DOCX)

**First published:**

14/05/2025

[View](/cs/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (462.86 KB - DOCX)

**First published:**

14/05/2025

[View](/da/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (481.3 KB - DOCX)

**First published:**

14/05/2025

[View](/de/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (453.26 KB - DOCX)

**First published:**

14/05/2025

[View](/et/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (470.85 KB - DOCX)

**First published:**

14/05/2025

[View](/el/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_el.docx)

français (FR) (469.84 KB - DOCX)

**First published:**

14/05/2025

[View](/fr/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (474.76 KB - DOCX)

**First published:**

14/05/2025

[View](/hr/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (457.4 KB - DOCX)

**First published:**

14/05/2025

[View](/is/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_is.docx)

italiano (IT) (482.94 KB - DOCX)

**First published:**

14/05/2025

[View](/it/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (450.49 KB - DOCX)

**First published:**

14/05/2025

[View](/lv/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (450.16 KB - DOCX)

**First published:**

14/05/2025

[View](/lt/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (461.65 KB - DOCX)

**First published:**

14/05/2025

[View](/hu/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (465.12 KB - DOCX)

**First published:**

14/05/2025

[View](/mt/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (465.46 KB - DOCX)

**First published:**

14/05/2025

[View](/nl/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (464.96 KB - DOCX)

**First published:**

14/05/2025

[View](/no/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_no.docx)

polski (PL) (480.35 KB - DOCX)

**First published:**

14/05/2025

[View](/pl/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_pl.docx)

português (PT) (463.16 KB - DOCX)

**First published:**

14/05/2025

[View](/pt/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_pt.docx)

română (RO) (428.66 KB - DOCX)

**First published:**

14/05/2025

[View](/ro/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (462.19 KB - DOCX)

**First published:**

14/05/2025

[View](/sk/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (463.25 KB - DOCX)

**First published:**

14/05/2025

[View](/sl/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (468.86 KB - DOCX)

**First published:**

14/05/2025

[View](/fi/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (454.73 KB - DOCX)

**First published:**

14/05/2025

[View](/sv/documents/product-information-tracked-changes/tobi-podhaler-epar-product-information-tracked-changes_sv.docx)

#### More information on Tobi Podhaler

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-03-140) on 17 April 2003. Tobi Podhaler was withdrawn from the Community register of orphan medicinal products in July 2023 at the end of the 12-year period of market exclusivity.

#### More information on Tobi Podhaler

- [EMEA-000184-PIP01-08-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000184-pip01-08-m02)
- [EMEA-000184-PIP03-16 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000184-pip03-16)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/12/2025

## Share this page

[Back to top](#main-content)